All In Biotech

Investigational drug · Phase 2

quaratusugene ozeplasmid

Also called: REQORSA

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Carcinoma, Non-Small Cell Lung, Small Cell Lung Cancer Extensive Stage.

Phase 2

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

3

Any phase or sponsor naming "quaratusugene ozeplasmid"

First trial start

2021

Sep 3, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "quaratusugene ozeplasmid", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Carcinoma, Non-Small Cell Lung
  • Small Cell Lung Cancer Extensive Stage

Approved drugs for the same conditions: Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "quaratusugene ozeplasmid" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Carcinoma, Non-Small Cell Lung

  • Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials

    Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

  • PF-08046054SGN-PDL1VPhase 32 trials

    Pfizer · Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.